BUZZ - Savara shares drop as FDA set to miss approval deadline for lung disease drug
路透社2026/11/20 14:26November 20 - ** Savara (SVRA.O) shares fell 18% pre-market to $4.27
** The company said the US Food and Drug Administration (FDA) has informed them it will not be able to complete the review of the experimental drug by the November 22 action deadline
** SVRA is seeking approval for molgramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis (PAP)—a rare lung disease characterized by abnormal accumulation
** The FDA review is still ongoing, and the agency has not provided a revised date
** As of the previous trading session close, the stock had fallen 13.6% year to date
(To facilitate non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to possible errors from automation, or missing context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for readers’ convenience. Reuters accepts no liability for any damages or losses arising from use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
DBS bets it can lose the deposit and keep the client

BUZZ-Comment: EUR/USD bears may face a fierce squeeze
Nvidia’s share price drops, pushing its market value below Alphabet

Bitcoin falls below $61,000, down 4.1% in 24 hours
